Analyzing determinants of premature trial discontinuation in leukemia clinical trials

Clinical trials are crucial for improving patient outcomes. Although a significant number of trials are discontinued prematurely, our understanding of factors influencing early termination is limited. We conducted a comprehensive search of ClinicalTrials.gov to identify leukemia trials from 2000 to 2020, followed by data abstraction performed by two independent reviewers. Among 3522 leukemia clinical trials identified, 28.4% were terminated prematurely. Slow accrual was the leading cause of termination 38.2%. The termination rate increased significantly from 17.0% between 2000 and 2005 to 30.9% between 2010 and 2015 (<i>p</i> < .001). Large trials had a lower termination rate than small trials (<i>p</i> < .001). Academic-sponsored trials had the highest termination rates compared to other sponsors' trials (<i>p</i> < .001). Early-phase trials showed higher termination rates compared to late-phase (<i>p</i> < .001). Other significant factors included a sequential assignment, single-center, and non-randomized trials (<i>p</i> < .001). Much of leukemia trials are terminated prematurely, with slow accrual being the most common reason for early termination.